News Archive

The content below is specific to Novartis Canada. To see all Novartis content, please visit the Novartis Global site.

2018

September

Media Release / Sep 13, 2018

Novartis employees complete 14th annual 600-km Ride for Life raising funds for Quebec Breast Cancer Foundation

Read More
Media Release / Sep 06, 2018

Novartis receives Health Canada approval of its CAR-T cell therapy, Kymriah™ (tisagenlecleucel)

Read More

August

Media Release / Aug 01, 2018

AimovigTM (erenumab), a novel treatment developed specifically for migraine prevention receives Health Canada approval

Read More

July

Media Release / Jul 13, 2018

Statement regarding recall of valsartan in generic medicines in Canada

Read More

June

Media Release / Jun 07, 2018

Addition of Cosentyx® to drug plan in Ontario and across Canada expands access to treatment for psoriatic arthritis and ankylosing spondylitis

Read More

May

Media Release / May 30, 2018

Novartis Canada celebrates annual Community Partnership Day across the country

Read More
Media Release / May 02, 2018

Health Canada approves KISQALI(TM) for the treatment of HR-positive and HER2-negative metastatic breast cancer in postmenopausal women in combination with letrozole as an initial endocrine-based therapy

Read More

February

Media Release / Feb 12, 2018

Novartis launches new awareness campaign for metastatic breast cancer community

Read More
2017

December

Media Release / Dec 05, 2017

Health Canada approves Rydapt(TM) (midostaurin), first targeted therapy for common form of acute myeloid leukemia (AML)

Read More

November

Media Release / Nov 30, 2017

Phase III STRIVE study data for erenumab (AMG334) in migraine prevention published in The New England Journal of Medicine

Read More

Pages